Tyr773
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr773  -  ITGB3 (human)

Site Information
DtANNPLyKEAtstF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448012
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 114 ) , [32P] bio-synthetic labeling ( 111 ) , immunoprecipitation ( 2 ) , mass spectrometry ( 1 , 4 , 6 , 7 , 9 , 10 , 14 , 15 , 16 , 17 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 80 , 81 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 107 , 108 , 109 , 110 ) , mutation of modification site ( 2 , 4 , 5 , 12 , 18 , 82 , 83 , 106 , 111 , 112 , 113 ) , peptide sequencing ( 111 ) , phospho-antibody ( 2 , 3 , 8 , 11 , 26 , 79 , 82 , 83 , 106 , 114 ) , western blotting ( 2 , 3 , 11 , 26 , 79 , 82 , 83 , 114 )
Disease tissue studied:
bladder cancer ( 22 , 23 , 33 ) , bone cancer ( 112 ) , brain cancer ( 64 , 66 ) , glioblastoma ( 66 ) , glioma ( 66 ) , breast cancer ( 20 , 34 , 39 , 68 , 91 , 92 ) , breast adenocarcinoma ( 39 ) , breast cancer, triple negative ( 68 ) , colorectal cancer ( 41 , 42 , 46 , 78 ) , colorectal carcinoma ( 41 , 42 , 46 , 78 ) , esophageal cancer ( 30 , 58 , 59 , 61 , 63 ) , esophageal carcinoma ( 63 ) , gastric cancer ( 15 , 25 , 47 ) , gastric carcinoma ( 15 ) , kidney cancer ( 21 , 28 ) , leukemia ( 19 , 27 , 31 , 32 , 40 , 48 , 51 , 52 , 54 , 55 , 56 , 65 , 70 , 71 , 75 , 76 , 80 , 81 , 83 , 86 , 96 , 109 , 113 ) , acute lymphocytic leukemia ( 27 , 86 , 96 ) , acute myelogenous leukemia ( 19 , 31 , 40 , 48 , 51 , 52 , 54 , 55 , 65 , 70 , 71 , 75 , 76 , 80 , 81 ) , chronic myelogenous leukemia ( 32 , 56 , 83 , 109 , 113 ) , lung cancer ( 8 , 15 , 35 , 53 , 62 , 69 , 73 , 77 , 84 , 87 , 89 , 90 , 94 , 97 , 99 , 102 , 103 , 104 , 105 ) , non-small cell lung cancer ( 8 , 15 , 53 , 62 , 69 , 73 , 77 , 84 , 87 , 89 , 90 , 94 , 97 , 99 , 102 , 103 , 104 , 105 ) , non-small cell lung adenocarcinoma ( 77 , 90 ) , non-small cell squamous cell lung carcinoma ( 89 ) , lymphoma ( 24 ) , Hodgkin's lymphoma ( 24 ) , neuroblastoma ( 1 , 64 ) , ovarian cancer ( 49 , 50 ) , ovarian epithelial carcinoma ( 49 ) , pancreatic cancer ( 101 ) , multiple myeloma ( 36 , 37 , 74 )
Relevant cell line - cell type - tissue:
293 (epithelial) [EFNB1 (human), transfection] ( 7 ) , 293 (epithelial) [EphB2 (human), transfection] ( 7 ) , 293 (epithelial) [FGFR1 (human), transfection] ( 9 ) , 293 (epithelial) ( 12 ) , 639V (renal) ( 21 ) , A549 (pulmonary) ( 104 , 105 ) , BC-3C (bladder cell) ( 22 ) , BxPC-3 (pancreatic) ( 101 ) , Caki-2 (renal) ( 29 ) , CAL-29 (bladder cell) ( 23 ) , CAL-85-1 (breast cell) ( 39 ) , CHO-K1 (fibroblast) ( 5 ) , CHP212 (neural crest) ( 1 , 64 ) , CHRF (megakaryocyte) ( 31 , 75 ) , DMS153 (pulmonary) ( 67 ) , DV-90 (pulmonary) ( 35 ) , E.coli (bacterial) ( 18 ) , EC (endothelial) ( 4 ) , GMS-10 (glial) ( 66 ) , HCC15 (pulmonary) ( 53 ) , HCC1937 (breast cell) ( 68 ) , HCC827 (pulmonary) ( 90 ) , HCEC (epithelial) ( 3 ) , HDLM-2 (lymphoid) ( 24 ) , HDQ-P1 (breast cell) ( 34 ) , HEK293T (epithelial) ( 95 ) , HEL (erythroid) ( 54 ) , HOS (bone cell) ( 112 ) , HT-29 (intestinal) ( 46 , 78 ) , Jurkat (T lymphocyte) ( 6 , 10 , 17 , 43 , 44 , 45 , 72 , 93 , 98 , 100 , 107 , 108 , 110 ) , K562 (erythroid) ( 32 , 56 , 57 , 82 , 83 , 106 , 109 , 111 , 113 ) , KG-1 (myeloid) ( 19 ) , KMS-11 (B lymphocyte) ( 37 ) , KMS-18 (B lymphocyte) ( 74 ) , Kyse140 (esophageal) ( 63 ) , Kyse270 (esophageal) ( 30 ) , Kyse410 (esophageal) ( 61 ) , Kyse450 (squamous) ( 59 ) , Kyse510 (esophageal) ( 58 ) , lung ( 69 ) , M-07e (myeloid) ( 81 ) , macrophage-blood ( 106 ) , Marimo (myeloid) ( 76 ) , MCF-10A (breast cell) ( 91 , 92 ) , MHH-NB-11 (neural crest) ( 1 ) , MKN-45 (gastric) ( 15 , 47 ) , MKPL-1 (megakaryoblast) ( 16 , 52 ) , MUTZ-5 (B lymphocyte) ( 27 ) , myeloid-bone marrow ( 40 , 48 , 51 , 55 , 65 ) , N87 (gastric) ( 85 ) , NCI-H1373 (pulmonary) ( 102 ) , NCI-H1650 (pulmonary) ( 97 ) , NCI-H1666 (pulmonary) ( 15 , 73 , 94 ) , NCI-H1944 (pulmonary) ( 77 ) , NCI-H1975 (pulmonary) ( 99 ) , NCI-H2066 (pulmonary) ( 62 ) , NCI-H2170 (squamous) ( 89 ) , NCI-H2347 (pulmonary) ( 87 ) , NCI-H3255 (pulmonary) ( 84 ) , NCI-H441 (pulmonary) ( 103 ) , NCI-H460 (pulmonary) ( 8 ) , OCI/AML3 (myeloid) ( 70 ) , OPM-1 (B lymphocyte) ( 36 ) , PA-1 (ovarian) ( 50 ) , PC9 (pulmonary) ( 38 ) , PL21 (myeloid) ( 71 ) , platelet-blood ( 11 , 14 , 26 , 79 , 114 ) , Scaber (squamous) ( 28 ) , SEM (B lymphocyte) ( 86 , 96 ) , SKNAS (neural crest) ( 1 ) , SKNDZ (neural crest) ( 1 ) , SKOV-3 (ovarian) ( 49 ) , SNU-5 (gastric) ( 25 ) , SNU-C2B (intestinal) ( 41 , 42 ) , UACC-812 (breast cell) ( 20 ) , UM-UC-1 (bladder cell) ( 33 ) , UT-7 (myeloid) ( 80 )

Upstream Regulation
Regulatory protein:
FGFR1 (human) ( 9 ) , TGM2 (human) ( 3 )
Putative in vivo kinases:
Src (human) ( 11 )
Treatments:
2-deoxyglucose ( 8 ) , A23187 ( 26 ) , anti-CD3 ( 10 ) , calphostin_C ( 83 ) , cell_adhesion ( 82 ) , FGF2 ( 9 ) , fibrinogen ( 79 ) , Mn(2+) ( 83 ) , peptide inhibitor ( 11 ) , phorbol_ester ( 83 ) , piceatannol ( 83 ) , PP1 ( 83 ) , RGD ( 82 , 83 , 111 , 114 ) , thrombin ( 11 , 26 , 114 ) , vanadate ( 26 , 83 ) , vitronectin ( 83 ) , wortmannin ( 83 ) , Y27632 ( 83 )

Downstream Regulation
Effects of modification on ITGB3:
activity, induced ( 4 , 82 ) , activity, inhibited ( 26 ) , intracellular localization ( 18 ) , molecular association, regulation ( 4 , 12 , 13 , 18 , 82 , 83 , 114 ) , protein conformation ( 4 ) , protein processing ( 26 )
Effects of modification on biological processes:
cell adhesion, altered ( 82 , 106 , 112 ) , cell adhesion, induced ( 4 ) , cell motility, altered ( 113 ) , cytoskeletal reorganization ( 106 )
Induce interaction with:
DOK1 (human) ( 13 ) , GRB2 (human) ( 114 ) , Pyk2 (human) ( 83 ) , VAV1 (human) ( 82 ) , tensin 1 (human) ( 18 )
Inhibit interaction with:
PVR (human) ( 12 ) , talin 1 (human) ( 13 )

References 

1

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

2

Simpson MA, et al. (2015) Direct interactions with the integrin β1 cytoplasmic tail activate the Abl2/Arg kinase. J Biol Chem 290, 8360-72
25694433   Curated Info

3

Tong L, et al. (2013) Molecular mechanism of transglutaminase-2 in corneal epithelial migration and adhesion. Biochim Biophys Acta 1833, 1304-15
23466867   Curated Info

4

Deshmukh L, et al. (2011) Tyrosine phosphorylation as a conformational switch: a case study of integrin β3 cytoplasmic tail. J Biol Chem 286, 40943-53
21956114   Curated Info

5

Bledzka K, et al. (2010) Tyrosine phosphorylation of integrin beta3 regulates kindlin-2 binding and integrin activation. J Biol Chem 285, 30370-4
20702409   Curated Info

6

Guo A (2010) CST Curation Set: 9180; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Jørgensen C, et al. (2009) Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326, 1502-9
20007894   Curated Info

8

Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33
19574224   Curated Info

9

Kasyapa C, et al. (2009) Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS. Proteomics 9, 3979-88
19658100   Curated Info

10

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

11

Su X, et al. (2008) RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood 112, 592-602
18398066   Curated Info

12

Nagamatsu Y, et al. (2008) Roles of Necl-5/poliovirus receptor and Rho-associated kinase (ROCK) in the regulation of transformation of integrin alpha(V)beta(3)-based focal complexes into focal adhesions. J Biol Chem 283, 14532-41
18364349   Curated Info

13

Oxley CL, et al. (2008) An integrin phosphorylation switch: the effect of beta3 integrin tail phosphorylation on Dok1 and talin binding. J Biol Chem 283, 5420-6
18156175   Curated Info

14

Zahedi RP, et al. (2008) Phosphoproteome of resting human platelets. J Proteome Res 7, 526-34
18088087   Curated Info

15

Guo A, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105, 692-7
18180459   Curated Info

16

Gu TL, et al. (2007) A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 110, 323-33
17360941   Curated Info

17

Possemato A (2007) CST Curation Set: 3061; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

McCleverty CJ, Lin DC, Liddington RC (2007) Structure of the PTB domain of tensin1 and a model for its recruitment to fibrillar adhesions. Protein Sci 16, 1223-9
17473008   Curated Info

19

Gu TL, et al. (2006) Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 108, 4202-4
16946300   Curated Info

20

Michaud C (2006) CST Curation Set: 2110; Year: 2006; Biosample/Treatment: cell line, UACC-812/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

21

Rikova K (2006) CST Curation Set: 2101; Year: 2006; Biosample/Treatment: cell line, 639L/serum starved; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Rikova K (2006) CST Curation Set: 2102; Year: 2006; Biosample/Treatment: cell line, BC-3C/serum starved; Disease: bladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Rikova K (2006) CST Curation Set: 2106; Year: 2006; Biosample/Treatment: cell line, CAL-29/serum starved; Disease: bladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Gu T (2006) CST Curation Set: 1935; Year: 2006; Biosample/Treatment: cell line, HDLM-2/untreated; Disease: Hodgkin's lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Guo A (2006) CST Curation Set: 1929; Year: 2006; Biosample/Treatment: cell line, SNU-5/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

26

Xi X, et al. (2006) Tyrosine phosphorylation of the integrin beta 3 subunit regulates beta 3 cleavage by calpain. J Biol Chem 281, 29426-30
16935858   Curated Info

27

Gu T (2006) CST Curation Set: 1874; Year: 2006; Biosample/Treatment: cell line, MUTZ-5/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Rikova K (2006) CST Curation Set: 1862; Year: 2006; Biosample/Treatment: cell line, Scaber/serum starved; Disease: cancer, squamous cell carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Rikova K (2006) CST Curation Set: 1815; Year: 2006; Biosample/Treatment: cell line, Caki-2/serum starved; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Yu J (2006) CST Curation Set: 1800; Year: 2006; Biosample/Treatment: cell line, Kyse270/serum starved; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Gu T (2006) CST Curation Set: 1791; Year: 2006; Biosample/Treatment: cell line, CHRF/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Moritz A (2006) CST Curation Set: 1751; Year: 2006; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

33

Rikova K (2006) CST Curation Set: 1741; Year: 2006; Biosample/Treatment: cell line, UM-UC-1/serum starved; Disease: bladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Michaud C (2006) CST Curation Set: 1736; Year: 2006; Biosample/Treatment: cell line, HDQ-P1/serum starved; Disease: breast ductal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Rikova K (2006) CST Curation Set: 1740; Year: 2006; Biosample/Treatment: cell line, DV-90/serum starved; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

36

Gu T (2006) CST Curation Set: 1725; Year: 2006; Biosample/Treatment: cell line, OPM-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

37

Gu T (2006) CST Curation Set: 1728; Year: 2006; Biosample/Treatment: cell line, KMS-11/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

38

Guo A (2006) CST Curation Set: 1720; Year: 2006; Biosample/Treatment: cell line, PC9/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

39

Michaud C (2006) CST Curation Set: 1695; Year: 2006; Biosample/Treatment: cell line, CAL-85-1/serum starved; Disease: breast adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

40

Gu T (2006) CST Curation Set: 1670; Year: 2006; Biosample/Treatment: bone marrow, myeloid/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

41

Li Y (2006) CST Curation Set: 1656; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

42

Li Y (2006) CST Curation Set: 1657; Year: 2006; Biosample/Treatment: cell line, SNU-C2B/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

43

Moritz A (2006) CST Curation Set: 1648; Year: 2006; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

44

Moritz A (2006) CST Curation Set: 1652; Year: 2006; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

45

Moritz A (2006) CST Curation Set: 1653; Year: 2006; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

46

Li Y (2006) CST Curation Set: 1639; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

47

Guo A (2006) CST Curation Set: 1605; Year: 2006; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

48

Gu T (2006) CST Curation Set: 1575; Year: 2006; Biosample/Treatment: bone marrow, myeloid/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

Guo A (2006) CST Curation Set: 1560; Year: 2006; Biosample/Treatment: cell line, SKOV-3/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

50

Guo A (2006) CST Curation Set: 1563; Year: 2006; Biosample/Treatment: cell line, PA-1/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

51

Gu T (2006) CST Curation Set: 1552; Year: 2006; Biosample/Treatment: bone marrow, myeloid/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

52

Gu T (2006) CST Curation Set: 1557; Year: 2006; Biosample/Treatment: cell line, MKPL-1/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

53

Guo A (2006) CST Curation Set: 1549; Year: 2006; Biosample/Treatment: cell line, HCC15/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

54

Gu T (2006) CST Curation Set: 1508; Year: 2006; Biosample/Treatment: cell line, HEL/untreated; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

55

Gu T (2006) CST Curation Set: 1457; Year: 2006; Biosample/Treatment: bone marrow, myeloid/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

56

Moritz A (2006) CST Curation Set: 1439; Year: 2006; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

57

Moritz A (2006) CST Curation Set: 1438; Year: 2006; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

58

Yu J (2006) CST Curation Set: 1395; Year: 2006; Biosample/Treatment: cell line, Kyse510/-; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

59

Yu J (2006) CST Curation Set: 1394; Year: 2006; Biosample/Treatment: cell line, Kyse450/-; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

60

Stokes M (2006) CST Curation Set: 1381; Year: 2006; Biosample/Treatment: cell line, 68-ES-9908/serum starved; Disease: glioblastoma multiforme; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

61

Yu J (2006) CST Curation Set: 1393; Year: 2006; Biosample/Treatment: cell line, Kyse410/-; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

62

Rikova K (2006) CST Curation Set: 1284; Year: 2006; Biosample/Treatment: cell line, NCI-H2066/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

63

Yu J (2006) CST Curation Set: 1245; Year: 2006; Biosample/Treatment: cell line, Kyse140/serum starved; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

64

Stokes M (2006) CST Curation Set: 1206; Year: 2006; Biosample/Treatment: cell line, CHP212/serum starved; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

65

Gu T (2006) CST Curation Set: 1177; Year: 2006; Biosample/Treatment: bone marrow, myeloid/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

66

Stokes M (2006) CST Curation Set: 1162; Year: 2006; Biosample/Treatment: cell line, GMS-10/serum starved; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

67

Farnsworth C (2006) CST Curation Set: 1077; Year: 2006; Biosample/Treatment: cell line, DMS153/serum starved; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

68

Rikova K (2005) CST Curation Set: 1034; Year: 2005; Biosample/Treatment: cell line, HCC1937/-; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

69

Guo A (2005) CST Curation Set: 977; Year: 2005; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

70

Gu T (2005) CST Curation Set: 954; Year: 2005; Biosample/Treatment: cell line, OCI/AML3/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

71

Gu T (2005) CST Curation Set: 955; Year: 2005; Biosample/Treatment: cell line, PL21/-; Disease: pancreatic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

72

Spek E (2005) CST Curation Set: 945; Year: 2005; Biosample/Treatment: cell line, Jurkat/pervanadate &'||' Rapigest lysis; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

73

Guo A (2005) CST Curation Set: 885; Year: 2005; Biosample/Treatment: cell line, NCI-H1666/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

74

Gu T (2005) CST Curation Set: 874; Year: 2005; Biosample/Treatment: cell line, KMS-18/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Gu T (2005) CST Curation Set: 842; Year: 2005; Biosample/Treatment: cell line, CHRF/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

76

Gu T (2005) CST Curation Set: 837; Year: 2005; Biosample/Treatment: cell line, Marimo/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Mitchell J (2005) CST Curation Set: 826; Year: 2005; Biosample/Treatment: cell line, NCI-H1944/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

78

Spek E (2005) CST Curation Set: 819; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

79

Vijayan KV, et al. (2005) The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases. J Biol Chem 280, 21756-62
15826939   Curated Info

80

Gu T (2005) CST Curation Set: 758; Year: 2005; Biosample/Treatment: cell line, UT-7/elastase; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

81

Gu T (2005) CST Curation Set: 723; Year: 2005; Biosample/Treatment: cell line, M-07e/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

82

Gao C, Schaefer E, Lakkis M, Blystone SD (2005) Beta3 tyrosine phosphorylation and alphavbeta3-mediated adhesion are required for Vav1 association and Rho activation in leukocytes. J Biol Chem 280, 15422-9
15699036   Curated Info

83

Butler B, Blystone SD (2005) Tyrosine phosphorylation of beta3 integrin provides a binding site for Pyk2. J Biol Chem 280, 14556-62
15695828   Curated Info

84

Guo A (2005) CST Curation Set: 647; Year: 2005; Biosample/Treatment: cell line, NCI-H3255/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

85

Spek E (2005) CST Curation Set: 627; Year: 2005; Biosample/Treatment: cell line, N87/serum starved &'||' EGF; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

86

Gu T (2005) CST Curation Set: 628; Year: 2005; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

87

Guo A (2005) CST Curation Set: 621; Year: 2005; Biosample/Treatment: cell line, NCI-H2347/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

88

Spek E (2005) CST Curation Set: 639; Year: 2005; Biosample/Treatment: cell line, DU 145/EGF; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

89

Rikova K (2005) CST Curation Set: 613; Year: 2005; Biosample/Treatment: cell line, NCI-H2170/serum starved; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

90

Guo A (2005) CST Curation Set: 601; Year: 2005; Biosample/Treatment: cell line, HCC827/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

91

Gu T (2005) CST Curation Set: 583; Year: 2005; Biosample/Treatment: cell line, MCF-10A/su 6656; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

92

Gu T (2005) CST Curation Set: 584; Year: 2005; Biosample/Treatment: cell line, MCF-10A/-; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

93

Spek E (2005) CST Curation Set: 578; Year: 2005; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

94

Guo A (2005) CST Curation Set: 552; Year: 2005; Biosample/Treatment: cell line, NCI-H1666/EGF; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

95

Gu T (2005) CST Curation Set: 5404; Year: 2005; Biosample/Treatment: cell line, 293T/bFGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

96

Gu T (2005) CST Curation Set: 515; Year: 2005; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

97

Moritz A (2004) CST Curation Set: 623; Year: 2004; Biosample1/Treatment/Isotope: cell line, NCI-H1650/EGF/L, Biosample2/Treatment/Isotope: cell line, NCI-H1650/EGF/Iressa/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

98

Spek E (2004) CST Curation Set: 510; Year: 2004; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

99

Guo A (2004) CST Curation Set: 502; Year: 2004; Biosample/Treatment: cell line, NCI-H1975/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

100

Spek E (2004) CST Curation Set: 406; Year: 2004; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

101

Guo A (2004) CST Curation Set: 412; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/EGF &'||' Iressa/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

102

Rikova K (2004) CST Curation Set: 354; Year: 2004; Biosample/Treatment: cell line, NCI-H1373/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

103

Rikova K (2004) CST Curation Set: 315; Year: 2004; Biosample/Treatment: cell line, NCI-H441/EGF; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

104

Farnsworth C (2004) CST Curation Set: 285; Year: 2004; Biosample/Treatment: cell line, A549/-; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

105

Farnsworth C (2004) CST Curation Set: 287; Year: 2004; Biosample/Treatment: cell line, A549/EGF; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

106

Chandhoke SK, et al. (2004) Beta 3 integrin phosphorylation is essential for Arp3 organization into leukocyte alpha V beta 3-vitronectin adhesion contacts. J Cell Sci 117, 1431-41
14996908   Curated Info

107

Goss V (2003) CST Curation Set: 2014; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

108

Goss V (2003) CST Curation Set: 2005; Year: 2003; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

109

Moritz A (2003) CST Curation Set: 31; Year: 2003; Biosample/Treatment: cell line, K562/pervanadate; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

110

Zhou J (2003) CST Curation Set: 1; Year: 2003; Biosample/Treatment: cell line, Jurkat/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

111

Blystone SD (2002) Kinetic regulation of beta 3 integrin tyrosine phosphorylation. J Biol Chem 277, 46886-90
12359711   Curated Info

112

Datta A, Huber F, Boettiger D (2002) Phosphorylation of beta3 integrin controls ligand binding strength. J Biol Chem 277, 3943-9
11723131   Curated Info

113

Blystone SD, et al. (1999) A molecular mechanism of integrin crosstalk: alphavbeta3 suppression of calcium/calmodulin-dependent protein kinase II regulates alpha5beta1 function. J Cell Biol 145, 889-97
10330414   Curated Info

114

Law DA, Nannizzi-Alaimo L, Phillips DR (1996) Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. J Biol Chem 271, 10811-5
8631894   Curated Info